Does essential thrombocytosis shorten life expectancy?

In general, ET is a chronic disease that does not shorten life expectancy in the first decade following diagnosis; however, over longer periods of time, survival may be shortened. Median survival of patients with ET is about 20 years.

Can you live a normal life with essential thrombocythemia?

Essential thrombocythemia, also known as ET, is a rare disease. The most important first fact about ET: on average, people with ET have a normal life expectancy. Patients with ET have increased numbers of platelets.

What is the survival rate for essential thrombocythemia?

The projected 10-year thrombosis-free, bleeding-free, and overall survival rates were 66%, 83%, and 80%, respectively.

Can thrombocytosis lead to leukemia?

In rare cases, essential thrombocytosis develops into polycythemia vera (PV), myelofibrosis, a myelodysplastic syndrome or acute myelogenous leukemia (AML).

Is thrombocytosis considered a disability?

In order for chronic thrombocytopenia to be considered disabling for Social Security Disability purposes, it must be severe.

What cancers cause thrombocytosis?

Thrombocytosis is an adverse prognostic factor in many types of cancer. These include breast cancer, ovarian and other gynecologic cancers, renal cell carcinoma and lung cancers.

Is essential thrombocytosis fatal?

Complications. Essential thrombocythemia can lead to a variety of potentially life-threatening complications.

Is essential thrombocythemia a terminal?

Essential Thrombocythemia (ET) On average, individuals with ET have a normal life expectancy if they are properly monitored and treated. In a small number of patients, the disease may transform to myelofibrosis, acute myeloid leukemia or, less frequently, myelodysplastic syndrome.

Which cancers cause high platelets?

A recent increase in the platelet count was associated with risk of colon cancer (OR, 5.52; 95% CI, 5.21-5.86), lung cancer (OR, 4.77; 95% CI, 4.51-5.04), ovarian cancer (OR, 7.23; 95% CI, 6.12-8.53), and stomach cancer (OR, 5.51; 95% CI, 4.82-6.29) (Figure 3 and eTable 7 in the Supplement).